AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions

Introduction: Cervical dystonia (CD) is a neurologic movement disorder with potentially disabling effects and significant impact on quality of life of those affected. AbobotulinumtoxinA (aboBoNT-A) was initially approved for a dilution of 500 U/1 mL and subsequently for a dilution of 500 U/2 mL, pro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/1b10f3346552463da42e87acfb171361
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares